Products Fludarabine + Cyclophosphamide + Tocilizumab
Fludarabine + Cyclophosphamide + Tocilizumab Phase 1 Recruiting 💤 Quiet Refractory Autoimmune Diseases
Refractory Autoimmune Diseases
Sep 4, 2025 → Aug 16, 2030
About Fludarabine + Cyclophosphamide + Tocilizumab Fludarabine + Cyclophosphamide + Tocilizumab is a phase 1 stage product being developed by Bristol Myers Squibb for Refractory Autoimmune Diseases. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07115745. Target conditions include Refractory Autoimmune Diseases.
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT07115745 Phase 1 Recruiting Sep 4, 2025 Aug 16, 2030 Refractory Autoimmune Diseases
Product Company Stage Hype Score Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomide Eli Lilly Phase 1/2 agenT-797 MiNK Therapeutics Phase 1 eFT508 + Avelumab eFFECTOR Therapeutics Phase 2 CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab) Celltrion Phase 3 Valemetostat Tosylate Daiichi Sankyo Phase 2 Enzalutamide Astellas Pharma Phase 2 ASP1650 Astellas Pharma Phase 2 YM598 Astellas Pharma Phase 2 erlotinib + etoposide Astellas Pharma Phase 2 Mitoxantrone Hydrochloride Liposome & Enlonstobart Sun Pharmaceutical Phase 1/2 Lenvatinib + Everolimus Eisai Phase 1/2 perampanel + perampanel + perampanel + Placebo Eisai Phase 3 Eribulin mesilate + Irinotecan hydrochloride Eisai Phase 1/2 perampanel Eisai Phase 2 rabeprazole sodium Eisai Pre-clinical Lenvatinib Eisai Phase 2 E2007 (perampanel) + E2007 (perampanel) + Placebo Eisai Phase 3 E2007 (perampanel) + E2007 (perampanel) + Placebo Eisai Phase 3 Tazemetostat Eisai Phase 2 Rufinamide Eisai Phase 3
Other Products from Bristol Myers Squibb